60Degrees_logo_RGB_Logo.jpg
60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study
20 mai 2024 07h59 HE | Sixty Degrees Pharmaceuticals
60 Degrees Pharmaceuticals funds a study at NC State to test for Babesia spp in chronic fatigue patients, aiming to link these infections to CFS symptoms.
60Degrees_logo_RGB_Logo.jpg
60 Degrees Pharmaceuticals Announces First Quarter 2024 Results
15 mai 2024 13h45 HE | Sixty Degrees Pharmaceuticals
SXTP posts Q1 2024 net product revenues increase of 515% year-over-year to $105.7 thousand in a Q1 earnings report released today.
60Degrees_logo_RGB_Logo.jpg
60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious Diseases
08 mai 2024 07h59 HE | Sixty Degrees Pharmaceuticals
60 Degrees Pharma plans clinical trial of Tafenoquine for Babesiosis. Letter to Journal of Infectious Diseases outlines protocol. Enrollment starts summer.
60Degrees_logo_RGB_Logo.jpg
60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required
02 mai 2024 07h59 HE | Sixty Degrees Pharmaceuticals
SXTP received FDA comments on tafenoquine-babesiosis trial protocol; no major changes are needed. Trial planning and execution to proceed as planned.
60Degrees_logo_RGB_Logo.jpg
60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine Babesiosis
03 avr. 2024 07h58 HE | Sixty Degrees Pharmaceuticals
60 Degrees Pharma (Nasdaq: SXTP) will sponsor a study using tafenoquine, an FDA-approved malaria drug, to treat canine babesiosis, a tick-borne disease.
60Degrees_logo_RGB_Logo.jpg
60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024
14 mars 2024 07h59 HE | Sixty Degrees Pharmaceuticals
60 Degrees Pharma advises of expected FDA response a month later than anticipated. Prepares for June 1, 2024, start of trial of tafenoquine for babesiosis.
60Degrees_logo_RGB_Logo.jpg
60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida auris
20 févr. 2024 07h59 HE | Sixty Degrees Pharmaceuticals
60 Degrees Pharmaceuticals will Sponsor Pre-Clinical Studies ofTafenoquine Use in Candida spp, Including Candida auris
60Degrees_logo_RGB_Logo.jpg
60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial Officer
08 févr. 2024 07h59 HE | Sixty Degrees Pharmaceuticals
Kristen Landon appointed Chief Commercial Officer at 60 Degrees Pharma leading ARAKODA® relaunch for malaria prevention and expanded tick-borne strategy.
60Degrees_logo_RGB_Logo.jpg
60 Degrees Pharmaceuticals Announces Closing of $2.4 Million Public Offering
31 janv. 2024 11h15 HE | Sixty Degrees Pharmaceuticals
60 Degrees Pharmaceuticals (Nasdaq: SXTP) closes $2.4 million public offering.
60Degrees_logo_RGB_Logo.jpg
60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million Public Offering
30 janv. 2024 09h00 HE | Sixty Degrees Pharmaceuticals
60 Degrees Pharma announces a $2.4 mil public offering, with funds to be used for working capital, relaunching ARAKODA for malaria prevention, and research